NCT01025570终止1 期
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination
研究概览
简要总结
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven adenocarcinoma of the pancreas.
- •Complete resection by standard pancreaticoduodenectomy (for tumors of the pancreatic head) or distal pancreatectomy (for tumors of the pancreatic tail). Positive microscopic margins are allowable.
- •No measurable disease.
- •ECOG performance status 0 -
- •≥ 18 years of age.
- •Ability to start adjuvant therapy within 8 weeks after pancreatic cancer surgery (but no sooner than 3 weeks).
- •CA 19-9 ≤ 2.5 times the upper limit of normal.
- •ANC (absolute neutrophil count) ≥ 1500/μL
- •Hemoglobin ≥ 9 gm/dL (may be transfused or may receive epoetin alfa to maintain this level)
- •Platelet count ≥ 100,000/μL
- •INR ≤ 1.5 (except those subjects who are receiving full-dose warfarin)
- •Total bilirubin ≤ 2.0 mg/dL
- •AST and ALT ≤ 2.5 times the upper limit of normal
- •Serum creatinine ≤ 2.0
- •Negative pregnancy test for women of childbearing potential (serum or urine beta-HCG).
- •All patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.
- •Women or men of reproductive potential must agree to use an effective contraceptive method during treatment and for 6 months afterwards.
- •At least one paraffin block from patient's pancreatic cancer surgery must be available for analysis (does not necessarily need to be received by the start of study treatment).
排除标准
- •Any prior systemic or investigational therapy for pancreatic cancer.
- •Grossly positive surgical margins.
- •Any of the following post-operative complications: wound dehiscence or infection, intraabdominal abscess, pancreatic or biliary leak or fistula.
- •History of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates the use of the investigational drugs in this protocol or that might render the subject at high risk of treatment related complications.
- •Serious active ongoing infection, including any requiring parenteral antibiotics.
- •Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapse.
- •Pregnancy (positive pregnancy test) or lactation.
- •Known central nervous system disease.
- •Inability to swallow pills/tolerate oral intake.
- •Inability to comply with study and/or follow-up procedures.
研究组 & 干预措施
Gem/Bos
Experimental
Gemcitabine 1000 mg/m2, D1,8,15 of each cycle
Bostutinib 400 mg daily concurrently with Gemcitabine
干预措施: Gemcitabine, Bosutinib (Drug)
结局指标
主要结局
To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination
时间窗: 2 years after last patient is enrolled
To evaluate the safety of using the combination of gemcitabine and bosutinib in the postoperative adjuvant treatment of patients with completely resected pancreatic cancer.
时间窗: 8 weeks after the 6th patient is enrolled
次要结局
- To determine the overall survival rates of patients with completely resected pancreatic cancer when treated postoperatively with the combination of gemcitabine and bosutinib(2 years after last patient is enrolled)
- To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination(2 years after last patient is enrolled)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic CancerPancreatic Cancer, Stage IBPancreatic Cancer, Stage IIAPancreatic Cancer, Stage IIBPancreatic Cancer Stage IIINCT05562297Shanghai Zhongshan Hospital50
已完成
2 期
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder CancerBladder CancerNCT00490880Eli Lilly and Company2
终止
2 期
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00523640University of Chicago30
已完成
2 期
Alimta and Gemcitabine in Non-Small Cell Lung CancerStage IIIB or IVNon-Small Cell Lung CancerNCT00434135Southern Italy Cooperative Oncology Group180
已完成
1 期
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic CancerPancreatic CancerNCT00316420Swedish Medical Center20